Mi Young Jeong
About Mi Young Jeong
Mi Young Jeong is an independent director of Reborn Coffee, Inc., age 60, first joining the Board in 2025. She is a registered nurse with over 30 years of clinical and leadership experience, serving as head nurse at UCI Medical Center since 2000; she holds a Bachelor of Nursing from Seoul National University . The Board has determined she is independent under Nasdaq standards .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| UCI Medical Center | Head Nurse | 2000–present | Clinical operations leadership |
External Roles
| Organization | Type | Role | Notes |
|---|---|---|---|
| UCI Medical Center | Academic medical center | Head Nurse | Since 2000 |
| Public company boards | — | — | None disclosed in proxy |
Board Governance
- Board and independence
- Director since 2025; Board size seven; independence affirmed under Nasdaq standards .
- Committee assignments and chair roles
- Compensation Committee member; Committee chaired by Andy Nasim (Jeong is not Chair). Audit Committee members are Farooq Arjomand (Chair), Andy Nasim, and Jung Jae Lim .
- Attendance and engagement
- Company disclosure states: “During fiscal 2024, the Audit Committee held no meetings and the Compensation Committee held no meetings. Each member of the Board attended at least 75% of the meetings that were held during the periods when they served as members of such committee.” No director-specific attendance percentages were provided. Note Jeong joined the Board in 2025 .
- Governance infrastructure
- Written charters for Audit and Compensation Committees posted on corporate website; Audit Committee financial expert identified as Farooq Arjomand .
| Committee | Role | Tenure on Committee | Meetings Held in 2024 | Chair? |
|---|---|---|---|---|
| Compensation | Member | Since 2025 (anticipated to remain post-Annual Meeting) | 0 | No |
| Audit | Not a member | — | 0 | — |
Fixed Compensation
- Non-employee director pay: The company disclosed that non-employee directors received no compensation for Board service in 2023 and 2024 .
| Director Pay Component | 2023 | 2024 |
|---|---|---|
| Annual retainer (cash) | $0 | $0 |
| Committee membership fees | $0 | $0 |
| Committee chair fees | $0 | $0 |
| Meeting fees | $0 | $0 |
| Equity (RSUs/DSUs) | $0 | $0 |
| Options | $0 | $0 |
Performance Compensation
- No performance-based director compensation framework was disclosed for non-employee directors in 2023–2024; no equity awards were reported for directors in those years .
| Performance-Linked Element | 2023 | 2024 |
|---|---|---|
| Cash bonus | $0 | $0 |
| Performance stock/units | $0 | $0 |
| Option grants | $0 | $0 |
No director-level performance metrics (e.g., TSR, revenue/EBITDA goals) were disclosed for non-employee directors .
Other Directorships & Interlocks
| Company/Organization | Public/Private/Non-profit | Role | Interlock/Conflict Note |
|---|---|---|---|
| — | — | — | No other public company directorships disclosed; no interlocks identified in proxy |
Expertise & Qualifications
- Proxy skills matrix indicates Jeong is credited for Management Experience; no marks for Financial, Capital Markets, Corporate Governance, Public Board, Industry, or Commercial experience in the matrix .
| Skill/Attribute | Indicated in Proxy Matrix |
|---|---|
| Management Experience | Yes |
| Financial Experience | No |
| Capital Markets Experience | No |
| Corporate Governance Experience | No |
| Public Board Experience | No |
| Industry Experience | No |
| Commercial Experience | No |
| Scientific Experience | No |
Equity Ownership
- Beneficial ownership as of October 3, 2025: Jeong reported no shares; table notes no shares identified are subject to a pledge .
| Holder | Shares Beneficially Owned | % Outstanding | Pledged Shares |
|---|---|---|---|
| Mi Young Jeong (Director) | 0 (—) | 0.0% | None (company notes no pledges in table) |
Shares outstanding used for calculation: 5,967,107 as of the determination date .
Related-Party Exposure
- No related-party transactions involving Jeong were disclosed. The proxy reports a January 2024 subscription agreement with Chairman Farooq M. Arjomand for 1,666,667 shares (~$1,000,000 gross proceeds) as a related-party transaction; none cited for Jeong .
Governance Assessment
- Independence and roles
- Independent director under Nasdaq standards; serves on the Compensation Committee (not Chair) .
- Alignment and incentives
- Non-employee directors received no cash or equity compensation for 2023–2024; Jeong reported zero beneficial ownership as of October 3, 2025; no pledging disclosed .
- Attendance and committee functioning
- Company disclosed no Audit or Compensation Committee meetings were held in 2024; general statement that members attended at least 75% of meetings held during their periods of service, without director-level detail (Jeong joined in 2025) .
- Qualifications for compensation oversight
- Skills matrix attributes Jeong with Management Experience, without marks for Financial, Capital Markets, or Corporate Governance experience, while she sits on the Compensation Committee .
- Conflicts and legal background
- No related-party transactions or legal proceedings involving Jeong were disclosed; no familial relationships disclosed among executives/directors .
RED FLAGS (facts-based)
- Audit and Compensation Committees held no meetings in 2024 (company-wide governance concern) .
- Director alignment: no director compensation in 2023–2024 and no reported share ownership for Jeong as of Oct 3, 2025 .